Sertraline protects against monocrotaline-induced pulmonary hypertension in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 11, 2006, Pages 1047-1051

  Li, Xue Qin ^a   Hong, Yang ^a   Wang, Yun ^a   Zhang, Xin Hua ^a   Wang, Huai Liang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Monocrotaline; Pulmonary hypertension; Selective serotonin re uptake inhibitor; Serotonin; Serotonin transporter; Sertraline

Indexed keywords

MESSENGER RNA; MONOCROTALINE; SERTRALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART INDEX; HEART RIGHT VENTRICLE; INFLAMMATION; LUNG ARTERY; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG PARENCHYMA; MALE; MORPHOLOGY; NONHUMAN; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; GENE EXPRESSION REGULATION; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; RATS; RATS, WISTAR; RNA, MESSENGER; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 33750072892     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04485.x     Document Type: Article

References (20)

1. MacLean MR, Herve P, Eddahibi S, Adnot S. 5-Hydroxytryptamine and the pulmonary circulation: Receptors, transporters and relevance to pulmonary arterial hypertension. Br. J. Pharmacol. 2000; 131: 161-8.
2. Wang HL, Dong X, Zhang XH, Xing J. 5-HT1B receptor augmented 5-HT vasoconstrictor response of pulmonary artery in monocrotaline-induced pulmonary hypertensive rats. Acta Pharmacol. Sin. 2001; 22: 269-73.
3. Eddahibi S, Raffestin B, Hamon M, Adnot S. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? J. Lab. Clin. Med. 2002; 139: 194-201.
4. Eddahibi S, Humbert M, Fadel E et al. Serotonin transporter overexpression in responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 2001; 108: 1141-50.
5. Eddahibi S, Fabbre V, Boni C et al. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells relationship with mitogenic action of serotonin. Circ. Res. 1999; 84: 329-36.
6. Marcos E, Fadel E, Sanchez O et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ. Res. 2004; 94: 1263-70.
7. Rabinovitch M. Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension. J. Clin. Invest. 2001; 108: 1109-11.
8. Lesch KP, Bengel D, Heils A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-31.
9. Eddahibi S, Chaouat A, Morrell N et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003; 108: 1839-44.
10. Slattery DA, Hudson AL, Nutt DJ. The evolution of antidepressant mechanisms. Fundam. Clin. Pharmacol. 2004; 18: 1-21.
11. Marcos E, Adnot S, Pham MH et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2003; 168: 487-93.
12. Wang HL. The serotonin receptor and transporter are potential therapeutic targets for pulmonary hypertension. Curr. Opin. Invest. Drugs 2004; 5: 963-6.
13. Guignaber C, Raffestin B, Benferhat R et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005; 111: 2812-19.
14. Kanai Y, Hori S, Tanaka T et al. Role of 5-hydroxytrptamine in the progression of monocrotaline induced pulmonary hypertension in rats. Cardiovasc. Res. 1993; 27: 1619-23.
15. Song D, Wang HL, Wang S, Zhang XH. 5-Hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells are extracellular signal-regulated kinase pathway dependent. Acta Pharmacol. Sin. 2005; 26: 563-7.
16. Eddahibi S, Hanoun N, Frisdal E et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest. 2000; 105: 1555-62.
17. Smoller JW, Pollack MH, Systrom D et al. Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatic 1998; 39: 24-9.
18. Laszlo A, Jonathan R, Harly G et al. Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disorders. Am. J. Psychiatry 1995; 152: 10.
19. Feiger AD, Flament MF, Boyer P, Gillespie JA. Sertraline versus fluoxetine in the treatment of major depression: A combined analysis of five double-blind comparator studies. Int. Clin. Psychopharmacol. 2003; 18: 203-10.
20. Hardman JG, Limbird LE (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn. McGraw-Hill, New York. 2001.